New York, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "In Vitro Diagnostics (IVD) Quality Control Global Market Report 2022" - https://www.reportlinker.com/p06228518/?utm_source=GNW
, Fortress Diagnostics, Seegene Inc. and Bio-Techne.
The global in-vitro diagnostics quality control market is expected to grow from $1.15 billion in 2021 to $1.23 billion in 2022 at a compound annual growth rate (CAGR) of 7.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1.54 billion in 2026 at a CAGR of 5.7%.
The in-vitro diagnostics (IVD) quality control market consists of sales of in-vitro diagnostics (IVD) quality control products by entities (organizations, sole proprietors, partnerships) that are used to evaluate and validate the reliability of in-vitro diagnostics testing systems. In-vitro diagnostics (IVD) quality control is a set of processes that ensure accuracy, performance, and environmental conditions impact on in vitro diagnostic tests including in vitro nucleic acid testing processes for pathogen detection, healthcare-associated infections (HAIs) such as pneumonia, urinary tract infections, and other conditions.
The main types of products in in-vitro diagnostics quality control are quality control products, data management solutions, and quality assurance services.The quality control products consist of serum/ plasma-based control products, whole blood-based control products, urine-based control products, and other control products manufactured by the IVD instrument manufacturers to cure mitigate or treat via in vitro diagnostics quality control.
The different manufacturer types include IVD instrument manufacturers, third-party quality control manufacturers and are used in various applications such as clinical chemistry, hematology, immunoassay, molecular diagnostics, microbiology, coagulation, or hemostasis, among others. It is implemented in various areas including hospitals, clinical laboratories, research and academic institutes, others.
North America was the largest region in the in vitro diagnostics (IVD) quality control market in 2021.Asia Pacific is expected to be the fastest-growing region in the forecast period.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The rise in the prevalence of infectious diseases such as HIV and cancer is significantly contributing to the growth of the in vitro diagnostics quality control market.Infectious diseases are common and caused by the transmission of pathogens such as viruses, bacteria, fungi, or parasites.
The rise in infectious diseases including HIV and cancer cases necessitates novel diagnostic testing goods and services for effective treatment, which is driving up demand for in vitro diagnostics quality control that ensure the accuracy, performance, and quality of test equipment and findings. For instance, according to the World Health Organization report, the number of HIV cases reached 37.7 million in 2020. In addition, in 2020, roughly 1.0 million individuals have died from HIV and 1.5 million have developed HIV-AIDS. Therefore, the rise in the prevalence of infectious diseases such as HIV and cancer is expected to drive the growth of the in-vitro diagnostics quality control market over the forecast years.
Increasing research and development is shaping the in vitro diagnostics quality control market.Research and development in the market are done for the development, introduction, and optimization of products and processes.
For instance, in August 2021, Microbiologics, a US-based biotechnology company introduced a new SARS-CoV-2 quality control (QC) tool for antigen point-of-care (POC) testing.The immobilized SARS-CoV-2 Whole Virus Antigen Control is extremely concentrated and contains fully intact genomic and viral proteins, making it appropriate for antigen testing as well as nucleic acid amplification studies (NAATs).
Microbiologics’ SARS-CoV-2 Whole Virus Antigen Control is the newest introduction to the company’s wide line of In Vitro Diagnostic (IVD) quality controls and Research Use Only (RUO) products developed to aid in the current COVID-19 pandemic response.
In January 2021, Cole-palmer, a US-based analytical products manufacturing company acquired Zeptometrix for an undisclosed amount.This acquisition will help Cole-Parmer to expand its quality controls and reference standards portfolio and to be a leading manufacturer for life sciences research and diagnostic testing.
Zeptometrix is a US-based company that manufactures a range of quality controls and verification panels for in-vitro diagnostics tests.
The countries covered in the in vitro diagnostics (IVD) quality control market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
Read the full report: https://www.reportlinker.com/p06228518/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
